Korro Bio

Korro Bio is a clinical-stage biopharmaceutical company developing a new class of genetic medicines based on RNA editing. Its proprietary OPERA platform uses oligonucleotides to recruit endogenous ADAR enzymes, which make precise single-base edits to RNA. Its lead programs target genetic and metabolic diseases, including alpha-1 antitrypsin deficiency (KRRO-110) and KRRO-121 for hyperammonemia.